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The metabolic aberrations associated with diabetes mellitus
profoundly alter the growth hormone/insulin-like growth factor I
(GH/IGF-I) system. In severe experimental diabetes, serum IGF-I
level is reduced, reﬂecting altered hepatic expression. On the other
hand, increased levels of kidney IGF-I have been implicated in the
development of diabetic kidney disease. This study aimed to exam-
ine the effect of mild experimental diabetes with hypoinsulinemia
on both the systemic and renal GH/IGF-I systems in a low-dose
streptozotocin (STZ)-induced diabetic rat. Diabetic animals with
mildhypoinsulinemiadevelopedrenalhyperﬁltrationwithin3days
of diabetes, whereas the renal size increased signiﬁcantly only be-
tween30and48daysofdiabetes.PlasmaGHlevelswereunchanged
during the entire course of the study, but a decrease in serum
IGF-I, IGF-binding protein 3 (IGFBP-3), and IGF-binding pro-
tein 4 (IGFBP-4) occurred after 10, 30, and 48 days. Kidney IGF-I
andIGF-bindingprotein1(IGFBP-1)mRNAexpressionincreased
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diabeticratsatleastpartlyduetodelayedchangesintherenalIGF
and IGF BPs.
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Diabetes mellitus is frequently associated with cardiovascu-
lar and kidney complications. The pathogenic mechanisms of
diabetic complications have not been fully elucidated, but lev-
els of both hyperglycemia and insulinemia trigger a cascade of
events leading to hemodynamic and morphology changes [1].
An active area of research has been to identify the mediators of
kidneycomplications,andtodeterminetherelationshipbetween
these mediators and the metabolic environment of diabetes.
The search for speciﬁc mediators for the diabetic nephropa-
thyhasbeenfocusedonthegrowthhormone/insulin-likegrowth
factor (GH/IGF) system [2–4]. In the diabetic state, alterations
of GH and the components of the IGF-I system have been found
in most tissues, including liver, kidney, retina, and endothelium.
The response of the IGF-I system to diabetes varies among tis-
sues. Circulating levels of IGF-I, representing primarily liver
production, decline in the diabetic state, whereas there is a sig-
niﬁcantincreaseinIGF-Iinthekidneyalmostimmediatelyafter
the onset of diabetes [5–7]. IGF-I is a renotrophic factor impli-
cated in the development of diabetic kidney disease, and it has
beenshownthatIGF-Iaccumulationisnecessaryforrenomegaly
as an early feature of diabetic nephropathy [8].
A family of IGF-binding proteins (IGFBPs) modulates the
effects of IGF-I. Levels of the different IGFBPs also change in
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diabetes, with IGFBP-1 increasing in the plasma and renal cor-
tex while others declining (IGFBP-3 in plasma and IGFBP-4
in plasma and kidney) [2]. The precise role of the IGFBPs as
mediators of diabetic kidney disease and other diabetic compli-
cationshasnotyetbeenclariﬁed.Ithasbeensuggestedthatsome
of these factors may potentiate the effect of IGF-I by ligation of
IGF-I to cell surface receptors [2].
The alterations in the GH-IGF axis have been related to the
severityofdiabetes.Inshort-termstreptozotocin(STZ)-induced
diabetes, changes in the plasma and renal levels of IGF are re-
lated to the dose of STZ administered to the rats [9]. Both high
blood glucose and low insulin levels have been related to the
changes in the IGF system in severe diabetes [6, 10–12]. How-
ever, the role of each of these factors have not been clearly
deﬁned, as it has been difﬁcult to distinguish between speciﬁc
effects of insulin and glucose. In the present study, we ana-
lyzed the effects of mild hypoinsulinemia on the GH-IGF axis
over a period of 7 weeks and its impact on the development of
diabetic kidney disease. In this model of hypoinsulinemia, hy-
perglycemia is limited to the nonfasting state; both insulin and
glucose levels are close to normal after overnight fasting. Our
results indicate that the same pattern of changes in the GH-IGF
axis seen in severe diabetes occurs also in mild diabetes, but at
a later stage. In addition, there was a temporal discrepancy be-
tween hyperﬁltration and development of renal hypertrophy in
mild hypoinsulinemic STZ rat, with the latter being dependent
on changes in the IGF system.
MATERIALS AND METHODS
Animals
Male Hebrew University Sabra rats, weighing 190 to 210
g, were used. The animals were maintained and treated in ac-
cordance with the regulations of the Hadassah-Hebrew Univer-
sity Center Committee on Animal Care and Use. Rats were
housed 3 per cage in a room with 12:12-hour artiﬁcial light
cycle, temperature 21±C § 2±C and humidity 55% § 2%. Mild
hypoinsulinemic, hyperglycemic diabetic state was induced by
a single intraperitoneal injection of freshly prepared STZ solu-
tion (50 mg/kg body weight diluted in dextrose 5%, pH 4.5).
To be included in the analysis, animals that received STZ had
to have a fasting blood glucose level <6.7 mM on 2 occasions,
monitoredwithportableglucose-measuringdevice(Glucometer
Elite, Bayer, Elkhart, IN, USA) and a nonfasting blood glucose
level >13.9 mM.
Throughout the study, all animals were maintained on stan-
dardlaboratoryratchowandprovidedwateradlibitum.At3,10,
30, and 48 days after the induction of diabetes, 8 diabetic and 8
age-matchedcontrolratswereplacedinmetaboliccages,during
which 24-hour urine samples were collected. Blood sample was
also taken from the tail vein. At the end of the study, the rats
were anaesthetized with an intraperitoneal injection of sodium
phenobarbital,andbloodwasdrawnfromtheaortaintoheparin-
containing tubes. Kidneys were rapidly removed, weighed, im-
mediately frozen in liquid nitrogen, and kept at ¡70±C until
analyzed.
Analytic Procedures
Plasma glucose concentration was measured by the glucose
oxidase method. Plasma insulin levels were determined by ra-
dioimmunoassay(RIA)usinghumaninsulinasastandard(Sorin
Biomedica, Saluggia, Italy). Plasma and urine creatinine lev-
els were determined by a standard automated application of
the Jaffe reaction [13]. Creatinine clearance was calculated by
standard laboratory method. Plasma GH was measured by RIA
(AmershamInternational,UK).SerumIGF-Iwasmeasuredafter
extraction in ethanol–acetic acid as previously described [6, 9].
Intra- and interassay coefﬁcients of variations were <5% and
<10%, respectively, for all assays.
Kidney IGF-I Extraction and Radioimmunoassay
IGF-I extraction was performed according to the method of
D’Ercoleaspreviouslydescribed[6,9,10].Brieﬂy,kidneyswere
homogenized in 1 mM acetic acid with an Ultra Turrax TD25
and further disrupted using a Potter Elvehjelm homogenizer.
The tissues were extracted twice. The sample was lyophilized
and subsequently redissolved in a 40 mM phosphate buffer, pH
8.0. Tissue extracts were kept at ¡20±C until the IGF-I assay
wasperformed.Alinearrelationshipwasfoundbetweenbiosyn-
thetic IGF-I and extracted IGF-I immunoreactivity at different
concentrations.ThemeasuredkidneyIGF-Iconcentrationswere
all corrected for IGF-I in serum entrapped in the kidney tissue
as previously described [11, 14].
Western Ligand Blotting (WLB) for IGFBPs
in Kidney and Serum
Approximately50mgofthawedkidneywashomogenizedas
previously described [15, 16]. Protein content was determined
by a commercial protein assay (Pierce Rockford, Rockford, IL)
using bovine serum albumin as a standard. Aliquots contain-
ing 200 ¹g of protein, or in a subset of experiments 2 ¹Lo f
plasma,wereelectrophoresedina10%sodiumdodecylsulfate–
polyacrylamide gel electrophoresis (SDS-PAGE) under nonre-
ducing conditions, and separated proteins were transferred by
electroelution to nitrocellulose paper (Schleicher and Schuell,
Munich, Germany). Membranes were incubated with approx-
imately 0.5£106 cpm [125I]-IGF-II (speciﬁc activity 2000
Ci/mmol, Amersham, UK) as detailed previously. Membranes
were washed Tris-HCl buffer (TBS) containing 0.1% Tween,
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x-ray. Speciﬁcity of the IGFBP band was conﬁrmed by compet-
itive coincubation with unlabeled IGF-II (Bachem, Bubendorf,
Switzerland). WLBs were quantiﬁed by densitometry using a
Shimazdu CS-9001 PC dual-wavelength ﬂying spot scanner.
RNase Protection Analysis
RNase protection assays were performed essentially as de-
scribed previously using probes to IGFBP-1 [16]. In brief, total
RNA was prepared from kidney tissue utilizing a ready RNA
kit according to the manufacturer’s instructions (Bet Haemek,
BiologicalIndustries,Israel).RNAwasquantiﬁedbyultraviolet
(UV) absorbance spectrophotometry. RNase protection by hy-
bridization was performed using 20 ¹g of total RNA according
to established protocols [17] using propes to IGFBP-1 [18]. Af-
ter hybridization, the samples were digested with RNase A and
T1(Ambion,Austin,TX),andtheprotectedfragmentsextracted
withphenol-chloroformandethanolprecipitated.Thefragments
were separated electrophoretically on an 8% polyacrylamide–
8 mM urea denaturing gel. Autoradiograms from each gel were
scanned by a densitometer (Molecular Dynamic, Sunnyvale,
CA). Changes in signals are expressed as the ratio between ex-
perimental and control values.
TABLE 1
Physical and biochemical parameters of the control and diabetic animals
3 days 10 days 30 days 48 days
Nonfasting glucose (mM)
Control 9.2 § 1.4 9.5 § 1.6 8.7 § 1.1 8.9 § 1.0
Diabetic 21.8 § 4.2¤ 22.9 § 6.2¤ 22.9 § 5.2¤ 27.6 § 5.9¤
Fasting glucose (mM)
Control ND 4.9 § 0.4 4.4 § 0.3 6.5 § 0.8
Diabetic ND 5.9 § 1.5 6.6 § 0.6 5.1 § 1.1
Nonfasting insulin (mU/L)
Control 45 § 18 39 § 15 49 § 10 37 § 13
Diabetic 29 § 15 34 § 23 29 § 82 2 § 7
Insulin/glucose ratio
Control 5.2 § 2.9 4.0 § 1.2 5.7 § 1.3 4.8 § 2.3
Diabetic 1.5 § 1.0¤ 1.0 § 0.2¤ 1.3 § 0.3¤ 1.2 § 0.5¤
Body weight (g)
Control 219 § 6 235 § 23 330 § 19 345 § 33
Diabetic 204 § 9¤¤ 225 § 17 213 § 49¤¤ 267 § 39¤¤
Kidney weight (g)
Control 0.84 § 0.09 0.98 § 0.08 1.12 § 0.12 1.00 § 0.09
Diabetic 0.88 § 0.10 0.94 § 0.09 1.11 § 0.18 1.37 § 0.21y
Kidney/100 g body weight
Control 0.38 § 0.04 0.41 § 0.03 0.34 § 0.03 0.29 § 0.03
Diabetic 0.43 § 0.05 0.42 § 0.04 0.52 § 0.08y 0.51 § 0.08y
Note. six to eight animals were used in each group at the indicated times. ND, not determined.
¤P<.001 compared with control animals; ¤¤P<.01 compared with control animals; yP<.05 compared
with control animals.
Statistical Analysis
Data are expressed as mean §SE. Each diabetic group was
compared with the age-matched control, and statistical signiﬁ-
cance between 2 groups was evaluated using unpaired 2-tailed
Student’s t test. Signiﬁcance was set as P value <.05.
RESULTS
The metabolic parameters of animals injected with 50 mg
STZ, which met the inclusion criteria, are listed in Table 1 to-
gether with the age-matched nondiabetic control animals. All
experimental animals had elevated serum glucose levels in non-
fasted state and near normal levels of glucose when overnight
fasted. Insulin levels in nonfasting state were not signiﬁcantly
lower than the values obtained in control animals. However, the
insulin/glucoseratiowassigniﬁcantlylowerindiabeticanimals,
indicating that an inadequate amount of insulin was secreted in
response to food intake. Compared with animals from earlier
experiments performed in our laboratory that received a higher
dose of 70 mg/kg STZ and had elevated fasting glucose and low
insulin levels, the low dose of STZ did result in marked weight
loss in diabetic rats only after 30 days (Table 1).260 M. KHAMAISI ET AL.
FIGURE 1
Creatinine clearance in control and mild STZ diabetic animals.
At the indicated time, nondiabetic (¤) and diabetic animals ( )
were placed in metabolic cages for 48 hours of adaptation,
during which 24-hour urine specimens were collected. Blood
samples were also collected from tail vein at the end of urine
collection. Results are expressed as mean C SE from 8 animals
in each group. ¤P<.05 compared with nondiabetic animals.
Despite the close to normal levels of insulin, the low STZ
dose animals showed signs of early renal changes. Creatinine
clearance (CrCl) was signiﬁcantly elevated at day 3, reaching a
2-fold increase when measured at 45 days after the induction of
diabetes, indicating that the alterations in kidney function were
progressive(Figure1).IncontrasttotherapidelevationinCrCl,
the increase in kidney size and in kidney/body weight ratio was
delayed, with signiﬁcant differences occurring only between 30
and 48 days after the induction of diabetes (Table 1).
The temporal discordance between changes in the CrCl and
renal hypertrophy prompted us to study the expression of IGF-I
and its binding proteins in both the systemic circulation and in
the kidney in animals with mild hypoinsulinemia. Both protein
and gene expression of the different components of the GH–
IGF-I axis were measured.
PlasmaGHlevelsinmildlydiabeticanimalsremainedsimilar
to the values obtained in the control animals during the entire
course of the study (Figure 2A). Plasma IGF-I levels were also
unchanged after 3 days but were reduced by 34%, 63%, and
30% after 10, 30, and 48 days after the induction of diabetes,
respectively (Figure 2B). Plasma 30-kDa IGFBPs (IGFBP-1/2)
were unchanged during the entire course of the study (data not
shown),whileIGFBP-3andIGFBP-4,similarlytoserumIGF-I,
were unchanged after 3 days but signiﬁcantly declined at day
10 and remained reduced during the entire course of the study
(Figure 3A, B).
In the kidney, IGFBP-1 mRNA levels were unchanged after
3daysbutwereelevatedby103%and40%,10and30daysafter
FIGURE 2
Plasma GH and IGF-I levels in control and mild STZ diabetic
animals. Plasma GH (A) was measured by radioimmunoassay.
Plasma IGF-I (B) was measured after extraction in
ethanol–acetic acid as described in Materials and Methods.
Results are expressed as mean C SE from 6 nondiabetic (¤)
and diabetic ( ) animals in each group. ¤P<.01 compared
with control animals.
theinductionofdiabetes,respectively(Figure4).Theincreasein
kidney IGFBP-1 gene expression was associated with a delayed
increase in kidney IGF-I, somewhat prolonged, and attenuated
inthemildhypoinsulinemicrats.IGF-Iwasincreasedby10%to
20%,10and30daysaftertheinductionofdiabetes,respectively,
compared with nondiabetic animals (Figure 5). Kidney 30-kDa
(IGFBP-1/2), IGFBP-3, and IGFBP-4 were unchanged after 3,
10, and 30 days, but increased signiﬁcantly at day 48 after the
induction of diabetes (Figure 6A, B, C).
To evaluate whether the increase in renal growth in the
mild hypoinsulinemic STZ diabetic rats was proportional to
the insulin/glucose ratio and the kidney IGF system, a corre-
lation study was carried out. A signiﬁcant correlation between
kidney/body weight ratio and insulin/glucose ratio (rD.59,
P<.05) (Figure 7A) was found. This correlation tended to be
stronger (rD.68, P<.05) in the animals after 30 and 48 days
of diabetes, at the time when mild hypoinsulinemia was shown
to increase renal growth (Figure 7B). To search which factor of
the kidney IGF system can positively predict and explain the
changes in kidney/body weight ratio, a correlation study was
performed.KidneyIGF-IlevelsandIGFBP-1mRNAcorrelatedMILD HYPOINSULINEMIA AND THE GH/IGF-I SYSTEM 261
FIGURE 3
Plasma IGFBP-3 and IGFBP-4 levels in control and mild
diabetic animals. Plasma IGFBP-3 (A) or IGFBP-4 (B) were
determined in the indicated times using Western ligand blotting
as described in Materials and Methods. Results are expressed
as mean C SE from 6 nondiabetic (¤) and diabetic ( ) animals
in each group. ¤P<.01 compared with control animals.
signiﬁcantlywithrenalhypertrophy(rD.57andrD.43,respec-
tively,P<.05)(Figure8A,B).Amildcorrelationwasalsofound
between kidney growth and kidney 30-kDa IGFBPs (IGFBP-
1/2) and IGFBP-4 (P<.05) (Figure 9A, C), without signiﬁcant
correlationwiththekidneyIGFBP-3levels(rD.27)(Figure9B).
DISCUSSION
In our study, we found that mildly hypoinsulinemic ani-
mals developed renal hyperﬁltration within 3 days of diabetes,
whereas an increase in kidney size and the kidney/body weight
ratio, markers for early diabetic kidney disease, were delayed,
with signiﬁcant differences occurring only between 30 and 48
days after the onset of diabetes. This is in contrast to severely
hypoinsulinemic rats given higher doses of STZ, in which
renomegaly developed already after 1 week of diabetes [18].
Plasma GH levels in diabetic animals were unchanged during
our study. This is in distinction to studies of others [19, 20]
showing a pronounced drop in GH levels in severely diabetic
rats. Plasma IGF-I levels were diminished signiﬁcantly on day
FIGURE 4
Kidney IGFBP-1 mRNA levels in nondiabetic and mild STZ
diabetic animals. Total kidney RNA from the 2 groups was
prepared, electrophoresed (20 ¹g), transferred, and hybridized
as described in Materials and Methods. Relative mRNA
amounts of IGFBP-1 was determined by densitometry and
expressed as means C SE in bar graphs from 6 nondiabetic (¤)
and diabetic ( ) animals in each group. ¤P<.03 compared
with control animals.
10, similar to the pattern seen in more severe diabetes, in which
the decline in GH levels is paralleled by a fall in serum IGF-I
beginning 5 to 7 days after the onset of diabetes [8, 18]. The fact
that a decline in IGF-I occurs despite the lack of changes in GH
levels suggests that there is a block in hepatic IGF-I production
FIGURE 5
Kidney IGF-I levels in control and mild STZ diabetic animals.
Kidney IGF-I extraction and measurement performed as
described in Materials and Methods. Values mean C SE from 6
nondiabetic (¤) and diabetic ( ) animals in each group.
¤P <.05 compared with control animals.262 M. KHAMAISI ET AL.
FIGURE 6
Kidney IGFBPs protein levels in control and mild STZ diabetic
rats. Total kidney proteins (200 mg) from the 2 groups were
subjected to SDS-PAGE on 10% polyacrylamide gels,
transferred to nitrocellulose, and incubated with [125I]-IGF-I as
described in Materials and Methods. Speciﬁcity of the 30-kDa
IGFBPs (IGFBP-1/2) (A), IGFBP-3 (B), and IGFBP-4 (C)
bands conﬁrmed by competitive coincubation with unlabeled
IGF-II. Results of the densitometric analysis are expressed as
mean C SE from 6 nondiabetic (¤) and diabetic ( ) animals in
each group. ¤P<.02 compared with control animals.
or increased clearance of serum IGF-I, even in the presence of
mild hypoinsulinemia. The decline in serum IGF-I levels have
been attributed to the decreased transcription rate of the IGF-I
gene in the liver [21]. This is consistent with the ﬁndings of
other workers who found that providing GH to hypopituitary-
orGH-deﬁcientratsfailedtoincreaseIGF-Ilevelsindiabeticrats
[8, 22]. Plasma IGFBP-3 and IGFBP-4 declined signiﬁcantly in
the diabetic animals from day 10. This pattern is also similar to




Correlation between insulin/glucose ratio and kidney/body
weight ratio in all animals (A), or the 2 groups after 30 and
48 days of induction of diabetes (B).
studied extensively and found to be related to multiple factors,
including insulin, IGF-I, GH, and glucocorticoids.
The discrepancy in time course between the rise in CrCl and
renomegaly raises the question as to whether different mecha-
nisms are involved in the development of kidney disease. In se-
vereexperimentaldiabetes,therapidincreaseinkidneysizeand
glomerular hypertrophy is associated with a transient increase
in renal IGF-I concentrations that peak at 24 to 48 hours and
subsequently return to normal by about 4 days [6]. Experimen-
talevidencesuggeststhattheincreaseinIGF-Iisresponsiblefor
renal hypertrophy, as infusion of IGF-I accelerated diabetic hy-
pertrophy [23]. Diabetic GH-deﬁcient dwarf rats do not show a
signiﬁcantincreaseinrenalIGF-I,withrenalhypertrophyslower
and milder [8]. IGFBP-1 increases signiﬁcantly in the renal cor-
tex after the induction of experimental diabetes, and it has been
suggestedthatIGFBP-1mediatestheeffectsofIGF-Ibyenhanc-
ingdeliveryofIGF-Itokidneycellsurface.Changesinthelevel
of this binding protein may be signiﬁcant in the development of
diabetic kidney disease [2].MILD HYPOINSULINEMIA AND THE GH/IGF-I SYSTEM 263
FIGURE 8
Correlation between the mean of kidney/body weight ratio and
the mean of kidney IGF-I (A) and mean of IGFBP-1 mRNA
(B) in the control and diabetic groups.
Comparing the data from mild hypoinsulinemic rats with di-
abetic dwarf rats provides an interesting contrast. Severely di-
abetic rats deﬁcient in GH have an early-attenuated increase in
IGF-I (which is blocked if insulin is administered) that returns
to normal at day 4 [8]. In contrast, the increase in renal IGF-I in
mildly hypoinsulinemic animals with an intact GH/IGF-I axis
is delayed and prolonged. This indicates that the metabolic al-
terations associated with the diabetic state may regulate renal
IGF-I levels both via the systemic GH/IGF-I axis and through
direct effects on renal IGF-I levels, possibly by modulation of
binding proteins. In the case of mildly hypoinsulinemic rats, it
is probable that the delay in renomegaly is due to the fact that
there is sufﬁcient residual insulin secretion to blunt the signif-
icant and rapid increase in renal IGF-I that is seen in severe
diabetes. The mechanism for the increase in renal IGF-I in mild
hypoinsulinemia may be different from that in severe hypoinsu-
linemia.Inmildlyhypoinsulinemicanimals,thereisasigniﬁcant
increase in renal IGFBP-3 and IGFBP-4 seen at 48 days. This is
incontrasttopreviousﬁndingswherenosigniﬁcantincreasewas
seen in IGFBPs in long-term severe diabetes [24, 25]. Our data
also suggest that there are other factors besides changes in renal
FIGURE 9
Correlation between kidney/body weight ratio and kidney
IGFBP-1/2 (A), IGFBP-3 (B), and IGFBP-4 (C) in control and
diabetic rats.
IGF-I levels that impact on diabetic kidney disease. Changes
in renal function occur early even in mild diabetes, despite that
the IGF-I system remains unchanged. The elevated CrCl seen in
these animals may result from either high glucose altering intra-
glomerular pressure or IGF-I–independent mechanisms such as
thenitricoxidesystem[26].Datafrommodelsofspontaneously
developing diabetes studied in other laboratories also indicate
that there may be different effects on either the morphology
or function of the kidney, depending on whether the animal is
severely diabetic and the type of diabetes (i.e., type 1 or type 2
diabetes) [25].
The traditional model of diabetic kidney disease employs a
severely hypoinsulinemic animal in which changes in kidney
morphologyandkidneyfunctionoccurveryearly,simultaneous
to the alterations in the levels of systemic and renal IGF-I. It is
probable that the diabetic kidney disease in clinical diabetes is
moresimilartothatofmildhypoinsulinemiaandthatthemecha-
nismsfortype2diabetesmaybeentirelydifferentbecauseofthe
elevated levels of insulin. To develop a better understanding of
diabetic kidney disease, it will be necessary to perform compre-
hensive studies on a variety of diabetic models to determine the264 M. KHAMAISI ET AL.
exactmechanismsbywhichalterationsinthemetabolicenviron-
ment transduce changes leading to the development of diabetic
kidney disease.
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